source
- Immunocore reports early data showing 70% two-year survival with brenetafusp/Kimmtrak combo in uveal melanomaImmunocore presented early clinical data on its bispecific T-cell engager combination brenetafusp and Kimmtrak in patients with uveal melanoma. The analysis, based on a subset of patients, indicat…
- Forge Biologics VP sees AI and Ohio talent driving next wave of gene therapy manufacturingSamantha Piteri-Molina, vice president of business and strategy at Forge Biologics, said her focus is on getting gene therapies into patients' hands. She helped steer Forge through a $620 million…